Veeva, a company involved in cloud software for the life sciences industry, and UCB, a global biopharmaceutical company, announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency. UCB will adopt Veeva ePRO and Veeva eConsent, to provide a patient-centric, digital experience to study participants and actively influence the strategic direction of these and other applications based on learnings.

Veeva ePRO is designed to simplify the design, management, and completion of electronic patient-reported outcomes (ePRO) with seamless data flow among sponsors, sites, and patients. Veeva eConsent is designed to simplify the set-up, completion, and review of consent for patients, sites, and study teams. Both applications are available to patients through MyVeeva for Patients, which provides one point of access for all their clinical trial actions, scheduling, and communications.

“The partnership between UCB and Veeva presents a significant opportunity to drive progress in clinical study execution,” said Iris Loew-Friedrich, executive vice president and chief medical officer at UCB. “By delivering digital clinical trials, we reduce the burden on participants and sites, improve trial accessibility, and ensure patients are at the heart of everything we do.”

“We’re excited to partner with UCB to advance patient-centric digital trials,” said Veeva CEO Peter Gassner. “Their input will help advance Veeva’s approach to solutions that make digital trials work even better for sponsors, sites, and patients.”